Dihexa is a prescription therapy used for cognitive support.

Patients seeking support for cognitive support may qualify after evaluation by a licensed provider.

Yes. Dihexa is a compounded medication that requires a valid prescription from a licensed provider. A telehealth consultation and medical intake are required before dispensing to ensure Dihexa is appropriate for your health history, goals, and current medications.

Dihexa is generally well-tolerated at therapeutic doses. Mild GI discomfort including nausea or loose stool has been reported in a small number of patients during initial oral dosing, which typically resolves as the body adjusts. Some patients report vivid dreams or mild sleep changes, consistent with Dihexa's influence on hippocampal and prefrontal signaling. Headache has been noted infrequently during the initial period of use. As with any compounded peptide therapy, individual responses vary. Report any unusual or persistent symptoms to your provider.

Dihexa is not appropriate for patients who are pregnant or breastfeeding, as safety data in these populations is insufficient. Patients with a history of hormone-sensitive or HGF/MET-pathway-related cancers should not use Dihexa without thorough oncological and provider evaluation, as HGF/MET activation has proliferative potential in certain cancer cell lines. Those with active seizure disorders or significant psychiatric conditions require individualized provider review, as potent modulation of hippocampal and prefrontal signaling may alter neurological stability. Dihexa has not been studied in pediatric populations and is not indicated for patients under 18. Disclose your full medical history and current medications before starting treatment.

Formal drug interaction studies for Dihexa have not been conducted. Because Dihexa acts on HGF/MET receptor signaling and modulates hippocampal neuroplasticity, patients on other nootropic agents including racetams, semax, or synapsin should disclose concurrent use, as additive cognitive stimulation may occur. Patients on angiotensin-system medications including ACE inhibitors or ARBs should discuss use with their provider given Dihexa's angiotensin IV derivation. Always provide a complete medication list to your provider before beginning treatment.

Patients with a history of malignancy should not use Dihexa without thorough oncological and provider evaluation, as HGF/MET pathway activation has proliferative potential in certain cancer cell lines. Those with active neurological conditions including epilepsy, schizophrenia, or bipolar disorder require careful provider review before starting, as potent synaptogenic and neuroplastic effects may interact with disease activity or medications. Patients with significant hepatic or renal impairment require individualized dosing review. Your provider requires a complete medical history before prescribing and will determine whether Dihexa is appropriate given your individual health profile.